Leqvio Office Injection vs Repatha Self-Injection at Home

What evolocumab is and how it fits into treatment

Evolocumab (Repatha) is a PCSK9 inhibitor: a monoclonal antibody, not a small-molecule pill, given by subcutaneous injection rather than taken orally. It works by binding circulating PCSK9, a protein that normally marks LDL receptors on liver cells for degradation. By neutralizing PCSK9, evolocumab lets more LDL receptors stay on the hepatocyte surface, which pulls additional LDL cholesterol out of the bloodstream. This is a well-established mechanism of action and is distinct from statins (which reduce cholesterol synthesis) and from ezetimibe (which blocks intestinal cholesterol absorption).

Evolocumab is FDA-approved as an adjunct to diet and, in most patients, to maximally tolerated statin therapy for adults with clinical atherosclerotic cardiovascular disease or certain forms of hyperlipidemia who need additional LDL-C lowering. It is not a substitute for statin therapy in patients who can tolerate one, and it is not FDA-approved as a first-line, statin-free therapy for routine primary prevention.

The FOURIER cardiovascular outcomes trial, published in the New England Journal of Medicine in 2017, evaluated evolocumab added to statin therapy in patients with established cardiovascular disease and found meaningful additional LDL-C lowering along with a reduction in major cardiovascular events over a multi-year follow-up. Because this draft could not independently re-verify the exact percentages and confidence intervals cited in earlier versions of this page, we describe the direction of the finding rather than repeat unverified precise figures. Readers and clinicians who need exact numbers for a treatment decision should pull the primary FOURIER publication or the current FDA label rather than rely on a secondary summary.

The single most important thing to know before you self-inject

Evolocumab self-injection is technically simple, but the FDA label is the only source that should govern your storage window, injection sites, and missed-dose timing, because those rules are the parts of this process most likely to be repeated incorrectly from memory. The device mechanics (autoinjector click, syringe plunger, Pushtronex light) are secondary to three fixed rules: never inject into bruised or hardened skin, never skip the visual confirmation of a completed dose, and never guess about a missed dose interval. When any of those three is uncertain, the correct action is to contact the prescriber or pharmacist before injecting again, not to repeat the injection on your own judgment. (See the current FDA prescribing information for Repatha for the full, up-to-date rules.)

Choosing among the three delivery devices

Amgen's FDA-cleared Repatha delivery formats differ in dosing schedule and hand mechanics, and the choice should be driven by the patient's dexterity, vision, and preferred schedule rather than by which device happens to be dispensed first.

SureClick autoinjector. A spring-loaded pen delivering a single 140 mg/mL dose. The patient presses it against the skin and holds it in place until a mechanical or visual signal confirms the dose is complete. This is the most commonly prescribed format for the every-2-week regimen because it requires the least manual dexterity.

Prefilled syringe. Same 140 mg/mL concentration, delivered by manually depressing the plunger. It gives more control over injection speed, which can reduce discomfort for some patients, but requires steady hand control and clear vision to gauge plunger travel. Patients with reduced hand strength, tremor, or low vision generally do better with the autoinjector.

Pushtronex on-body infusor. Delivers the full 420 mg once-monthly dose over roughly five minutes through an adhesive patch worn on the abdomen. It requires no manual injection action once activated, but it does require the patient to stay reasonably still and avoid dislodging the device during delivery, and to correctly read the completion indicator before removing it.

According to the FDA label, the choice between the every-2-week (140 mg) and once-monthly (420 mg) schedule is a prescribing decision, and the device is matched to that schedule rather than chosen independently of it.

Storage and preparation before injection

Evolocumab must be refrigerated at 2°C to 8°C in its original carton, protected from light, and never frozen. If a device has been frozen at any point, discard it; freezing can degrade the protein and is not reversible by thawing.

About 30 minutes before an injection, remove one device from the refrigerator and let it warm at room temperature on its own. Do not use a microwave, hot water, or direct sunlight to speed this up; injecting a cold solution increases discomfort and is not how the device is validated for use. The FDA label describes a limited allowance for room-temperature storage once a device is removed from the refrigerator, after which any unused device must be discarded regardless of the original expiration date. Confirm the exact number of allowed days against the current label insert in the package, since this kind of storage detail can be revised between label updates and should not be relied on from memory (checked as of this article's last review date above).

Before injecting, look at the solution through the device window. It should be clear to slightly opalescent and colorless to pale yellow. A device with visible particles, discoloration, or a past expiration date should not be used. Do not shake any of the three devices at any point; shaking can damage the protein.

Step-by-step: SureClick autoinjector

1. Gather supplies. One SureClick autoinjector at room temperature, an alcohol swab, a cotton ball or gauze, and an FDA-cleared sharps container.
2. Select and clean the site. Acceptable sites are the front of the thigh, the abdomen (avoiding roughly a 2-inch radius around the navel), or the outer upper arm (caregiver-administered only). Rotate sites with every injection. Clean with the alcohol swab and let the skin air-dry fully. Do not inject into skin that is bruised, tender, red, or hardened.
3. Remove the cap. Pull the cap straight off; do not twist. A small drop of liquid at the needle tip is normal.
4. Position and inject. Pinch the skin at the cleaned site, place the autoinjector at a 90-degree angle against it, and press the button firmly. Hold the device in place until the mechanical and visual signals indicate the dose is complete; do not lift it early.
5. Remove and dispose. Lift the device straight up. The needle guard should lock automatically. Dispose of it immediately in the sharps container. Never recap a used device.

Injection-site reactions (mild redness or soreness) are a recognized but generally minor and self-limited side effect of evolocumab. Persistent redness beyond about 48 hours, spreading redness, or swelling should be reported to the prescriber rather than treated at home.

Step-by-step: prefilled syringe

The syringe follows the same warm-up and site-preparation steps as the autoinjector, with a manual injection step. Remove the needle cap by pulling it straight off. Pinch the skin and insert the needle at an angle appropriate to the amount of subcutaneous tissue (this is something a nurse or pharmacist should demonstrate at the first injection, since the right angle varies by body habitus). Depress the plunger slowly and steadily until it is fully down, then release the pinched skin, withdraw the needle, and apply gentle pressure with gauze if a drop of blood appears.

Patients who have trouble gripping the syringe barrel or controlling plunger speed often do better switching to the autoinjector, and this is a reasonable thing to raise with the prescribing clinician rather than something to push through independently.

Decision guide: which device, and what to do when something looks wrong

This is not medical advice for an individual dose decision. It is a structured way to think through the choices and failure points that actually change what a patient should do next.

1. Choosing a device up front

2. What to do when a signal is unclear (failure-mode checklist)

• No confirmation click or indicator appeared on the autoinjector, or the syringe plunger did not reach the bottom: do not assume the dose was complete. Do not inject a second full dose on your own. Contact the prescriber or pharmacist to determine whether a partial dose occurred and what to do next.
• The Pushtronex device detached before the light turned solid green: treat this the same way, as a possible incomplete dose, and call before repeating.
• The solution looked cloudy, discolored, or contained particles: do not use that device regardless of how the injection would otherwise go. Use a different device if available and report the defective one.
• A dose was missed by 7 days or less: per FDA labeling, give the dose as soon as possible and resume the regular schedule.
• A dose was missed by more than 7 days: skip that dose and resume on the next originally scheduled date. Do not double a dose to make up for a missed one.
• Injection-site redness lasts beyond about 48 hours, spreads, or is accompanied by fever: this is outside routine self-management and should be reported to the prescriber.
• Facial swelling, difficulty breathing, or rapid heartbeat after injection: this is a possible allergic reaction and warrants urgent medical evaluation, not a wait-and-see approach.

3. What this framework does not cover

It does not replace in-person training from the prescribing clinic before a first self-injection, and it does not set an individualized dosing schedule, which must come from the prescriber.

Step-by-step: Pushtronex on-body infusor

The Pushtronex system is used only for the 420 mg once-monthly dose. It attaches to the abdomen and delivers the dose over roughly five minutes.

Remove the infusor kit from the refrigerator about 30 minutes before use. Peel the adhesive liner and attach the device to the abdomen, away from the navel and away from any area under a waistband where friction could dislodge it. Press the start button; the device inserts its own needle and begins delivery automatically. During delivery, avoid bending sharply at the waist or lying directly on the device. A solid light and audible signal indicate the infusion is complete; if that signal never appears, treat it as a possible incomplete dose and contact the care team rather than assuming success.

Site rotation and minimizing discomfort

Injecting repeatedly in the same spot can cause lipohypertrophy or lipoatrophy, changes in the fat layer that can affect how consistently the drug is absorbed. The FDA label recommends rotating among the abdomen, thigh, and upper arm.

A simple rotation habit, such as alternating left thigh, right thigh, left abdomen, and right abdomen across consecutive doses, combined with a phone note of the last site used, avoids accidental reuse of the same spot. Letting the solution reach full room temperature and injecting slowly both tend to reduce discomfort; a brief cold pack before cleaning the site can help patients who are especially sensitive.

Monitoring after starting Repatha

Prescribers typically order a fasting lipid panel some weeks after starting therapy to confirm the LDL-C response, with the exact interval set by the individual prescriber rather than a fixed universal rule. Very low LDL-C levels on treatment have not been shown, in the trials that have specifically studied cognitive outcomes with evolocumab, to be associated with impaired cognitive function, though this remains an area where guideline bodies continue to watch long-term data rather than treat the question as fully closed.

Routine liver enzyme or creatine kinase monitoring is not specifically required for evolocumab and is generally driven instead by concurrent statin therapy, if any. Patients on evolocumab should still watch for and report signs of a serious allergic reaction (facial swelling, difficulty breathing, rapid heartbeat), which are recognized but uncommon.

Traveling with Repatha

Evolocumab needs cold-chain handling during travel. An insulated case with gel packs, not dry ice, keeps the device within its labeled temperature range without risking a freeze. Devices generally tolerate standard airport security screening. Carrying a prescription copy or physician's letter can help at security checkpoints and when transporting sharps disposal containers, since sharps rules vary by country and by airline. If continuous refrigeration will not be possible, mark the date the device leaves the refrigerator and discard it once the labeled room-temperature window has passed, regardless of the original printed expiration date.

What is established, what is plausible, and what is not established

Established: Evolocumab lowers LDL-C by inhibiting PCSK9 and increasing LDL receptor recycling. It is FDA-approved as an add-on to statin therapy (or diet alone in specific populations) for LDL-C lowering, delivered subcutaneously via three specific devices with defined storage and site rules described in the FDA label.

Plausible but not fully quantified in this draft: The precise magnitude of cardiovascular risk reduction from the FOURIER trial and the exact rate of successful home self-injection reported in device-specific studies are widely cited in the literature, but this draft does not carry forward specific percentages from the prior version because those figures could not be re-verified against a confirmed primary source during this revision. A reader who needs an exact number for a clinical or coverage decision should pull the original FOURIER publication and the current FDA label rather than a secondary summary.

Not established from the material available here: Any claim about a specific pain score, exact injection-site reaction rate compared with placebo, or a specific percentage of patients who self-inject correctly without assistance should be treated as unverified until confirmed against the primary study, and none of those exact figures are asserted in this draft.

When to seek care rather than manage this at home

Contact the prescriber promptly if a device malfunctions and you cannot tell whether a full dose was delivered, if injection-site redness spreads or persists beyond about two days, or if LDL-C remains far above target despite confirmed, consistent dosing (which may prompt evaluation for familial hypercholesterolemia or an added non-statin agent). Seek urgent medical attention for facial swelling, difficulty breathing, or rapid heartbeat after an injection, which can indicate a serious allergic reaction.

This article is intended for general education about self-injection technique and does not replace individualized instruction from the prescribing clinician or pharmacist, or the current FDA-approved label. It is pending qualified medical review.